Davos WEF 2022 | Why Kumar Mangalam Birla Passed On A Chance To Buy Ambuja Cements, ACC
India's biggest cement maker passed on an opportunity to become even bigger when Holcim Group put up two of its leading cement companies for sale.
“I don't think this deal makes sense for us financially,” said Kumar Mangalam Birla, chairman of Aditya Birla Group—the owner of UltraTech Cement Ltd. “I think we have better options of growth,” he told BQ Prime's Menaka Doshi on the sidelines of the World Economic Forum 2022 summit at Davos.
Billionaire Gautam Adani acquired Ambuja Cements Ltd. and ACC Ltd. held by Holcim. The value for the Holcim stake and open offer consideration for the cement companies is nearly $10.5 billion (about Rs 81,400 crore).
“Price is in the eyes of the beholder. For us, I don't think we could have created value as much as we can in other options that we're looking at,” Birla said.
“We are sort of entrenched in the business in a very positive way. We have been in the business for several decades now. We are very entrenched with the channels that form the ecosystem of the business,” Birla said. “We have a large market share, our brand commands a premium, is loved by consumers, and we have our own plans that we intend to go ahead with, as we would have even otherwise. It's always good to have competition. We have been used to competition.”
Birla, however, said UltraTech's plans won't change due to Adani's entry. “I don't think we are going to start bidding for assets much more aggressively only because there's a new entrepreneur in the sector. That's not how it works for us. It must create value.”
Watch the full interview here:
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.